- Artic Securities and Carnegie will host the event on Friday, June 2, 2023, at
11:00 a.m. CEST -
BERGEN, Norway, May 30, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announced today that the Company will participate in
an investor webcast and Q&A session hosted by Arctic Securities and Carnegie on
Friday, June 2, 2023, at 11:00 a.m. CEST.
Chief Executive Officer Martin Olin and Chief Financial Officer Rune Skeie are
scheduled to attend and discuss BerGenBio's clinical development program and the
ongoing rights offering.
Investors may attend the event by contacting Arctic Securities by
mail events@arctic.com or Carnegie by mail ca@carnegie.no.
Presentation used in the webcast will be uploaded to the investor section of the
Company's website www.bergenbio.com/investors/presentations.
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com.
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.